We propose LPAR5 serves as a lipid-regulated immune checkpoint which impairs anti-tumor immunity through multiple mechanisms that include metabolic reprogramming of tumor-specific CD8 T cells and direct inhibition of antigen receptor-induced T cell activation. Here, CD8A is linked to neoplasm.